Quantinno Capital Management LP Buys 5,652 Shares of Waters Corporation $WAT

Quantinno Capital Management LP grew its stake in shares of Waters Corporation (NYSE:WAT) by 8.4% during the first quarter, Holdings Channel reports. The institutional investor owned 72,709 shares of the medical instruments supplier’s stock after buying an additional 5,652 shares during the period. Quantinno Capital Management LP’s holdings in Waters were worth $21,653,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Anchor Investment Management LLC purchased a new stake in Waters in the 1st quarter worth approximately $27,000. Zions Bancorporation National Association UT lifted its holdings in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 40 shares in the last quarter. Vision Retirement LLC purchased a new position in Waters during the first quarter valued at approximately $29,000. Bollard Group LLC bought a new position in shares of Waters in the first quarter worth approximately $29,000. Finally, Louisbourg Investments Inc. bought a new position in shares of Waters in the first quarter worth approximately $30,000. 94.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Morgan Stanley raised their price objective on shares of Waters from $350.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Wolfe Research initiated coverage on shares of Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 target price for the company. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a research note on Wednesday, July 8th. Sanford C. Bernstein assumed coverage on Waters in a report on Friday, June 26th. They set an “outperform” rating and a $435.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Waters in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $401.60.

Waters Trading Down 0.7%

Shares of WAT opened at $377.75 on Friday. The firm has a market cap of $37.09 billion, a P/E ratio of 48.00, a price-to-earnings-growth ratio of 2.28 and a beta of 1.20. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The company has a 50 day simple moving average of $369.30 and a two-hundred day simple moving average of $345.48.

Waters (NYSE:WAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the firm earned $2.25 earnings per share. The company’s quarterly revenue was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, equities analysts expect that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.